477 related articles for article (PubMed ID: 30053900)
1. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B
Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
3. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Andersson M; Kamby C; Knoop AS;
Cancer; 2010 May; 116(9):2081-9. PubMed ID: 20186830
[TBL] [Abstract][Full Text] [Related]
5. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
[TBL] [Abstract][Full Text] [Related]
6. High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial.
Nielsen TO; Jensen MB; Burugu S; Gao D; Jørgensen CL; Balslev E; Ejlertsen B
Clin Cancer Res; 2017 Feb; 23(4):946-953. PubMed ID: 27601592
[No Abstract] [Full Text] [Related]
7. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
8. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
[TBL] [Abstract][Full Text] [Related]
9. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.
Cheang MC; Voduc KD; Tu D; Jiang S; Leung S; Chia SK; Shepherd LE; Levine MN; Pritchard KI; Davies S; Stijleman IJ; Davis C; Ebbert MT; Parker JS; Ellis MJ; Bernard PS; Perou CM; Nielsen TO
Clin Cancer Res; 2012 Apr; 18(8):2402-12. PubMed ID: 22351696
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
[TBL] [Abstract][Full Text] [Related]
12. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
[TBL] [Abstract][Full Text] [Related]
13. Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
Lænkholm AV; Jensen MB; Eriksen JO; Roslind A; Buckingham W; Ferree S; Nielsen T; Ejlertsen B
Clin Breast Cancer; 2020 Aug; 20(4):e423-e432. PubMed ID: 32253134
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
15. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
Jakesz R; Hausmaninger H; Kubista E; Gnant M; Menzel C; Bauernhofer T; Seifert M; Haider K; Mlineritsch B; Steindorfer P; Kwasny W; Fridrik M; Steger G; Wette V; Samonigg H;
J Clin Oncol; 2002 Dec; 20(24):4621-7. PubMed ID: 12488405
[TBL] [Abstract][Full Text] [Related]
16. The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes.
Laenkholm AV; Jensen MB; Eriksen JO; Buckingham W; Ferree S; Nielsen TO; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):44-50. PubMed ID: 29202609
[TBL] [Abstract][Full Text] [Related]
17. Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.
Bago-Horvath Z; Rudas M; Singer CF; Greil R; Balic M; Lax SF; Kwasny W; Hulla W; Gnant M; Filipits M
Clin Cancer Res; 2020 Nov; 26(21):5682-5688. PubMed ID: 32546648
[TBL] [Abstract][Full Text] [Related]
18. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
[TBL] [Abstract][Full Text] [Related]
19. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.
Ejlertsen B; Jensen MB; Nielsen KV; Balslev E; Rasmussen BB; Willemoe GL; Hertel PB; Knoop AS; Mouridsen HT; Brünner N
J Clin Oncol; 2010 Feb; 28(6):984-90. PubMed ID: 20038724
[TBL] [Abstract][Full Text] [Related]
20. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]